Analysts: Merck’s Gardasil undervalued by billions of dollars
Wolfe Research analysts say the market is underestimating the vaccine’s potential by more than $2 billion.
Wolfe Research analysts say the market is underestimating the vaccine’s potential by more than $2 billion.
The healthcare ecosystem is changing rapidly to succeed requires the adoption of key account management (KAM), a systematic, robust alternative to the traditional buyer/seller model.
The American Medical Association announced it is partnering with Sermo, the online community for physicians.
Lyons Lavey Nickel Swift is rebranding as “LyonHeart” under its proprietary creative-strategic process dubbed “Disruption.”
GlaxoSmithKline is in Congressional crosshairs over its marketing of Avandia, and investors arent happy either.
Onyx and Bayers kidney cancer drug Nexavar (sorafenib) was also found to extend the lives of liver cancer patients in a clinical trial by almost three months, or 44%, doctors said.
InVentiv Health has acquired brand identity shop Addison Whitney.
The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).
The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).
Pfizer won’t be allowed to present new data on its closely watched developmental drug torcetrapib at the annual American Heart Association (AHA) meeting this week.
Please login or register first to view this content.